BNP PARIBAS ARBITRAGE/PUT/MODERNA/90/0.01/20.09.24 | Real-time Borsa Italiana 07:01:40 2024-06-27 am EDT | ||
| 0.024 EUR | +20.00% |
|
| Current month | +81.82% | ||
| 1 month | +233.33% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
MODERNA, INC.
| Date | Price | Change |
|---|---|---|
| 24-06-27 | 0.024 | +20.00% |
| 24-06-26 | 0.02 | +100.00% |
| 24-06-25 | 0.01 | -4.76% |
| 24-06-24 | 0.0105 | -16.00% |
| 24-06-21 | 0.0125 | 0.00% |
Real-time Borsa Italiana
Last update June 27, 2024 at 07:01 am EDT
More quotesStatic data
| Product type | Plain-Vanilla-Warrants |
|---|---|
| Buy / Sell | PUT |
| Underlying | MODERNA, INC. |
| Issuer | 
BNP Paribas
|
| P21639 | |
| ISIN | NLBNPIT21639 |
| Date issued | 2024-03-26 |
| Strike | 90 $ |
| Maturity | 2024-09-20 (86 Days) |
| Parity | 100 : 1 |
| Emission price | - € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 0.086 € |
|---|---|
| Lowest since issue | 0.0055 € |
| Spread | 0.0145 € |
| Spread % | 45.31% |
Company Profile
Moderna, Inc. is a biotechnology company specialized in research and development of therapeutics and vaccines for cancer, infectious, autoimmune and cardiovascular diseases. Net sales break down by type of revenue as follows:
- revenue from product sales (95.7%) ;
- revenues from grants (4%);
- revenues from collaboration agreements (0.3%).
At the end of 2021, the group possessed a portfolio of 15 products in clinical development, of which 3 in phase III, 8 in phase II and 4 in phase I, and 12 products in preclinical development.
Net sales are distributed geographically as follows: the United States (33.4%), Europe (37.1%) and other (29.5%).
Sector
-
Consensus: Moderna, Inc.
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
25
Last Close Price
122.4
USD
Average target price
145.9
USD
Spread / Average Target
+19.11%
- Stock Market
- Warrants
- P21639 Warrant
